Eli Lilly and Company $LLY Shares Bought by NorthStar Asset Management LLC NJ

NorthStar Asset Management LLC NJ lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,383 shares of the company’s stock after purchasing an additional 199 shares during the quarter. Eli Lilly and Company comprises about 0.5% of NorthStar Asset Management LLC NJ’s investment portfolio, making the stock its 26th biggest position. NorthStar Asset Management LLC NJ’s holdings in Eli Lilly and Company were worth $1,857,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in LLY. PNC Financial Services Group Inc. lifted its holdings in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Nuveen LLC purchased a new stake in Eli Lilly and Company in the first quarter valued at approximately $4,613,912,000. Vanguard Group Inc. increased its position in Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Eli Lilly and Company by 106.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after purchasing an additional 765,010 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Eli Lilly and Company by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after buying an additional 682,203 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,048.90 on Thursday. The firm has a market capitalization of $991.61 billion, a PE ratio of 68.56, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,055.59. The stock’s 50 day moving average price is $844.09 and its 200 day moving average price is $784.22. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the business earned $1.18 EPS. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 29.35%.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Morgan Stanley increased their target price on Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Berenberg Bank restated a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Finally, Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research note on Wednesday. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,027.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.